CRLX101: Phase II data

Cerulean reported data from 18 patients with platinum-resistant ovarian cancer in the first stage of an open-label, U.S. Phase II trial showing that 15 mg/m 2

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE